Type 2 Diabetes Clinical Trial
— LBW-SSRIOfficial title:
Effects of 3 Months of SSRI-Treatment on Metabolism and HPA-axis in Young Men Born With Low Birth Weight - a Randomized, Double Blinded and Placebo-controlled Trial
Verified date | May 2013 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chronic stress has been proposed to be involved the development of western life-style
diseases such as cardiovascular disease and type 2 diabetes (T2DM). At the same time chronic
stress is also believed to cause psychiatric disease such as melancholic depression (MD)and
anxiety disorders.
Accordingly, humans born with low birth weight (LBW) (ei. less than 5,0 LB) display an
increased risk for T2DM and MD. Studies suggest stress and adrenal stress hormones
(glucocorticoids) (GCC) might be involved in the development of both of these conditions.
Recent studies of animals born LBW suggest, that SSRI-compounds, usually employed in the
treatment of MD-related diseases, reduces stress-responses and levels of stress hormones
such adrenal steroids and at the same time has a positive influence on glucose metabolism.
In present study, the investigators aim to measure levels of GCC and stress and assess
glucose metabolism in healthy young men (20-35 years) born LBW (40 subjects). The volume and
structure of a certain brain area (ie. hippocampus) involved in regulation of adrenal GCC
and known to be malfunctioning in chronically stressed individuals will be assessed by
magnetic resonance imaging (MRI). Further metabolic examination will be accompanied by MRI
spectroscopy of liver and muscle fat content as well as total fat content (Dexa-scanning)
and contents of fat in the abdomen (by MRI) . Psychiatric well-ness and symptoms will be
characterized by well-established questionnaires such as MDI and SCL-92 and responses as
regards blood pressure, heart rate and changes in basal plasma concentrations of GCC and
Epinephrine will be assessed while performing a Stroop Stress Test. Finally, a 24 hour blood
pressure profile test will be included.
After this extensive examination program, subjects will be randomized to 3-4 months of
treatment with either Escitalopram (an SSRI-compound) or Placebo. Subsequently, at the end
of the treatment, the whole examination program will be repeated to detect potential
beneficial changes.
A group of young normal birth weight men (20 subjects) will serve as a healthy baseline
group for comparison and will not be exposed to any medical treatment.
This trial will add understanding to the mechanism underlying the development of type 2
diabetes and depression in LBW. Additionally, present trial might be capable of proposing a
novel treatment strategy to prevent the development of these diseases in LBW man.
Status | Completed |
Enrollment | 60 |
Est. completion date | April 2014 |
Est. primary completion date | September 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 20 Years to 35 Years |
Eligibility |
Inclusion Criteria: 1. Healthy men 20-35 years old. 2. birth weight <2500g. 3. Born at gestational week 38- 40 (42). Exclusion Criteria: 1. Diabetes, insulin-resistance or precursors in first degree relatives or maternal gestational diabetes. 2. Small parents(mother <160cm and/or father <170cm). 3. History of abuse of alcohol, medicine og drugs in the mother during pregnancy. 4. Liver of renal failure : s-ALAT > 2.5 normal upper limit (>175µM) or s-creatinine >125 µmol/l. 5. Co-morbidity that after at medical examination is considered to be a problem. 6. BMI>25.5 7. Smoking that is considered to be an issue as regards completing the study. 8. Treatment with a MAO-inhibitor. 9. Born before gestational week 38. 10. Participation in larger X-ray examinations such CT-scans during the last 12 months. 11. Participation in medical experiments or treatments involving intravenous administration of radioactive substances during the last 12. Ongoing medical treatment that will be considered a issue for completing the study. 13. Allergy towards the substance Escitalopram. 14. Metal parts in the body that contra-indicates MRI. 15. Ongoing medical treatment thrombocyte inhibiting substances such as NSAIDS. 16. Previous gastrointestinal bleeding or gastro-duodenal ulcers. 17. Depression during examination or treatment 16/05-2011: Criterias updated - added 17 and adjusted 6. from BMI >25 to BMI >25.5 |
Country | Name | City | State |
---|---|---|---|
Denmark | Medical Dep M, Diabetes and Endocrinology Aarhus University Hospital, Aarhus Sygehus | Aarhus |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in rate of glucose dissappearance | Changes in LBW-subjects from baseline vs. post-treatment after 3 months treatment with placebo or Escitalopram | ||
Primary | Changes in the 24-hour AUC of free plasma cortisol | Changes in LBW-subjects from baseline vs. post-treatment after 3 months treatment with placebo or Escitalopram | ||
Secondary | 24 hour basal plasma cortisol/ACTH profile as measured every 3rd hour. | before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | hippocampic volume and structure as assessed by MRI | All limbic structures (amygdala, thalamus, hippocampus and ventromedial prefrontal cortex) were morphologically and volumetrically analyzed. | before and after 3 months of treatment with placebo or Escitalopram | |
Secondary | 24 hour bloodpressure profile | before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | MRI spectroscopy of fat in skeletal muscle tissue | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | MRI spectroscopy of fat in liver | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | Abdominal fat as assessed by MRI | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | MDI questionnaire scores | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | SCL-92 questionnaire scores | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | Fasting blood lipid profile | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | Ratio between insulin and glucose concentrations in blood during an oral glucose tolerance test (OGTT) | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | Whole body fat content as assessed by a dexa scanning | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | Hepatic insulin sensitivity as assessed suppression of endogenous glucose production (calculated by infusion of 3H-labelled glucose) | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | 10 pm to midnight basal plasma ACTH/cortisol concentration ratio as measured by blood sampling every 10th minute. | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | increase in blood pressure and heart rate during Stroops Stress test | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | Increase in plasma ACTH, cortisol and epinephrine concentrations during Stroops Stress Test | before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | SRPAS questionnaire scores | Self Reported Physical Activity Questionaire | Before and after 3 months of treatment with placebo or Escitalopram | |
Secondary | Actigraph GT3X activity monitoring | Objective measurements of physical activity in 96 hours at home | Before and after 3 months of treatment with placebo or Escitalopram | |
Secondary | Whole body bone mass density and T-/Z-scores as assessed by a dexa scanning | Before and after 3 months of treatment with placebo or Escitalopram | ||
Secondary | Plasma-Inflammation markers | Before and after 3 months of treatment with placebo or Escitalopram |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |